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Introduction: Splenic metastasis from ovarian carcinoma generally presents as peritoneal spread with multiorgan
involvement. Fewer than 30 cases of solitary parenchymal splenic metastasis from ovarian carcinoma have been
published in the literature. The presentation is often asymptomatic.
Case presentation: An increase in tumor marker CA-125 from 18.1 to 132.6 units/ml (normal <35 units/ml) was
measured in a 56-year-old Israeli Jewish woman who had undergone, six years previously, a total abdominal
hysterectomy with bilateral salpingo-oophorectomy due to right ovarian carcinoma. An abdominal computed
tomography scan revealed a mass of 6×8cm at the anterior of the spleen, with close proximity to the wall of the
stomach. A gastroscopy demonstrated exterior pressure on the stomach body. An open splenectomy was
performed to exclude a peritoneal carcinomatosis. No intraoperative evidence of tumoral spreading in the
abdominal cavity was observed, other than the spleen. The final histologic result demonstrated a high-grade
carcinoma consistent with metastatic endometrioid-type ovarian carcinoma grade 3.
Conclusions: This case highlights the importance of cancer antigen 125 assessment and medical imaging in the
follow-up of ovarian carcinoma. Open laparotomy, or laparoscopy, enables exclusion of a peritoneal carcinomatosis,
which is more common than solitary parenchymal splenic metastasis, as was presented in the current case.
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Metastasis of malignant tumors to the spleen is rare. Until
recently the literature was based on autopsy studies, which
reported frequencies of 2.3 to 7.1 percent [1,2] or splenec-
tomy specimen studies, which reported a frequency of 1.3
percent [3]. According to data based on clinical course and
evaluation, approximately 1 percent of malignant tumors
metastasize to the spleen [4]. Splenic metastasis is generally
part of multivisceral metastatic disease, with breast, lung,
ovarian, colorectal and gastric carcinomas and skin melan-
oma the most common origins [5,6]. In Compérat et al.’s
review of 93 cases published through 2006 [6], colorectal
and ovarian carcinoma demonstrated the highest frequency
as the primary source. Metastasis from ovarian carcinoma
to the spleen is generally a part of peritoneal spreading with
multiorgan involvement, generally involving the splenic* Correspondence: ohatoum@gmail.com
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reproduction in any medium, provided the orcapsule. Fewer than 30 cases of solitary parenchymal
splenic metastasis from ovarian carcinoma have been pub-
lished in the literature.Case presentation
A 56-year-old Israeli Jewish woman was admitted to our
surgical ward for a splenectomy due to a solitary splenic
mass. Six years prior to her admission she had undergone
a total abdominal hysterectomy with bilateral salpingo-
oophorectomy due to carcinoma in the right ovary. The
histology examination revealed an endometrioid carcin-
oma, grade 3. Staging with International Federation of
Gynecology and Obstetrics (FIGO) classification was 1A.
Following the surgery, our patient received chemotherapy
treatment with paclitaxel (Taxol®) and carboplatin.
Tumor marker cancer antigen (CA)-125 was evaluated
every year following the operation. Subsequent to a rise in
CA-125 from 18.1 to 132.6 units/ml (normal <35 units/ml),
our patient was referred for an imaging and an endoscopic
assessment.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Abdominal computed tomography. Abdominal
computed tomography revealed a heterogeneous hypodense mass
of the spleen with suspected necrotic changes.
Figure 3 Spleen and adherent fat tissue specimen after
resection.
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a mass of 6×8cm at the anterior of the spleen (Figure 1),
with close proximity to the wall of the stomach. There was
no other indication of a secondary tumor spreading in the
abdomen. Her chest CT scan was normal. A gastroscopy
demonstrated exterior pressure on the stomach body. All
the specimens from gastric mucosa that were taken with
the gastroscope and that were subjected to histologic test-
ing were normal except a chronic inflammation in the
gastroesophageal area. A colonoscopy also showed normal
results. A bone isotopic scan revealed no abnormalities.
Our patient was asymptomatic and her gynecologic
and abdominal examinations were without any remark-
able findings such as tenderness or splenomegaly.
An open laparotomy through a left subcostal incision
was performed to exclude a peritoneal carcinomatosis. The
laparotomy did not reveal any abdominal pathology except
in the spleen. Neither peritoneal washing for cytologicFigure 2 Spleen and adherent fat tissue specimen after
resection.examination nor peritoneal biopsies were taken. A total
splenectomy was then performed (Figures 2 and 3). No
intraoperative evidence of tumoral spreading in the ab-
dominal cavity was observed, other than in the spleen.
Our pathologic laboratory received a 550gram spleen,
9×11×17cm in dimensions, with fat tissue adhered to
the spleen. Inside the spleen, we observed a tumor con-
sistent with a high-grade metastatic endometrioid car-
cinoma grade 3 (Figures 4 and 5). Inside the adherent
fat tissue, we observed another tumor with a diameter
of 5cm, with the same characteristics as the splenic
tumor.
The postoperative period was uneventful. Our patient
was discharged from our ward a few days post surgery
and was examined again two weeks later in our clinic,
without any signs of operation-induced complications
such as intra-abdominal bleeding, intra-abdominal in-
fection or surgical site infection. CA-125 levels droppedFigure 4 Splenic parenchyma with high-grade metastatic
carcinoma (hematoxylin and eosin, ×40 original magnification).
Figure 5 Metastatic ovarian carcinoma demonstrates strong
positive estrogen receptor staining (estrogen receptor, ×200
original magnification).
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oncologic clinic, and received another course of chemo-
therapy, again with paclitaxel (Taxol®) and carboplatin.
Discussion
Splenic metastasis originates mostly from ovarian, breast,
and lung carcinoma, and from melanoma. Solitary paren-
chymal splenic metastases are rare and often asymptom-
atic. Splenic metastasis from ovarian cancer is usually
diagnosed during follow-up examinations, and is mainly
based on elevation of CA-125 and imaging studies [7].
Mostly, ovarian carcinoma metastasizes through the peri-
toneal cavity to cause a visceral spreading that may include
the capsule of the spleen. Solitary parenchymal metastases
of the spleen are most probably generated through the
hematogenic route, which is rare due to several mecha-
nisms, including rhythmic contractions of the splenic cap-
sule, the sharp angle of the splenic artery branching from
the celiac artery, lack of afferent lymphatic vessels to the
spleen and mostly - the inhibitory effect of the splenic
microenvironment on the growth of metastatic cells [6].
In our case, we found no signs of peritoneal cavity me-
tastases and the only metastases found were inside the
spleen and in the adherent fat tissue, therefore, we as-
sume that in this case the carcinoma metastasized hema-
togenically, and the tumor in the adherent fat tissue
represents an extension of the splenic metastasis.
Increased diagnosis of solitary splenic metastasis is ap-
parently due to improved and routine use of medical im-
aging [6]. In the current case, a rise in CA-125 prompted
CT scanning. The six-year period that transpired between
the original surgery to remove an ovarian carcinoma and
detection of splenic metastasis is similar to the 57-month
mean (range 28 to 88) between surgery for stage III dis-
ease and splenectomy reported in a series of six womenwith solitary splenic metastasis of ovarian carcinoma [8].
In a separate report, a solitary splenic metastasis of
12×8×5.5cm was detected by abdominal ultrasonog-
raphy 20 years after surgery for an ovarian carcinoma.
That patient was asymptomatic and tumor markers, in-
cluding CA-125, were in the normal range [9].
Most cases of solitary splenic metastasis documented
in the literature were diagnosed with stage III disease
(FIGO classification), and underwent optimal tumor
debulking [10]. The histological finding of the case de-
scribed here was high-grade carcinoma consistent with
metastatic endometrioid-type ovarian carcinoma, grade
3, stage 1A (FIGO classification). In Compérat et al.’s
review, 17 of the 18 cases of splenic metastases with ori-
gins in ovarian cancer were serous cystadenocarcinoma
and the remaining case was mucinous cystadenocarci-
noma [6]. Elsewhere, a metachronous solitary splenic
metastasis from an ovarian carcinosarcoma of dimen-
sions 30cm×27cm×20cm was detected seven years after
a bilateral salpingo-oophorectomy [11].
Most of the documented splenectomies were per-
formed in an open versus laparoscopic procedure. Even
though laparoscopic procedures have advantages such as
faster recovery, shorter hospital stay and the possibility
of earlier initiation of postoperative chemotherapy, de-
bate persists as to the optimal treatment, mainly due to
the possibility of peritoneal dissemination.
Conclusions
The current case highlights that splenic metastasis should
be suspected when an elevated CA-125 level is measured
during follow-up of ovarian carcinoma, and should be
confirmed using imaging studies such as ultrasound and
CT scan. Splenectomy is the treatment of choice. Further
studies are needed to determine the effectiveness of the
laparoscopic versus open procedure [12,13].
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Abbreviations
CA: cancer antigen; CT: computed tomography; FIGO: International
Federation of Gynecology and Obstetrics.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DK (Dror Karni), a third-year resident, participated in the operation,
conducted the literature review and wrote the first draft of this case report.
DK (Doron Kopelman), the Head of General Surgery B’ at Haemek Medical
Center, helped in writing the manuscript, and approved the final version.
OAH was the leading surgeon who performed the operation, and a major
contributor to writing the manuscript. All authors read and approved the
final manuscript.
Karni et al. Journal of Medical Case Reports 2014, 8:154 Page 4 of 4
http://www.jmedicalcasereports.com/content/8/1/154Received: 21 May 2013 Accepted: 3 February 2014
Published: 17 May 2014
References
1. Berge T: Splenic metastases. Frequencies and patterns. Acta Pathol
Microbiol Scand A 1974, 82:499–506.
2. Hirst AE Jr, Bullock WK: Metastatic carcinoma of the spleen. Am J Med Sci
1952, 223:414–417.
3. Kraus MD, Fleming MD, Vonderheide RH: The spleen as a diagnostic
specimen: a review of 10 years’ experience at two tertiary care
institutions. Cancer 2001, 91:2001–2009.
4. Sauer J, Sobolewski K, Dommisch K: Splenic metastases–not a frequent
problem, but an underestimate location of metastases: epidemiology
and course. J Cancer Res Clin Oncol 2009, 135:667–671.
5. Lam KY, Tang V: Metastatic tumors to the spleen: a 25-year clinicopathologic
study. Arch Pathol Lab Med 2000, 124:526–530.
6. Compérat E, Bardier-Dupas A, Camparo P, Capron F, Charlotte F: Splenic
metastases: clinicopathologic presentation, differential diagnosis, and
pathogenesis. Arch Pathol Lab Med 2007, 131:965–969.
7. Ghani AA, Hashmi ZA, Chase DM, Patel SB, Jones DF: Intraparenchymal
metastases to the spleen from ovarian cancer: a case report. J Med Case
Rep 2010, 4:30.
8. Gemignani ML, Chi DS, Gurin CC, Curtin JP, Barakat RR: Splenectomy in
recurrent epithelial ovarian cancer. Gynecol Oncol 1999, 72:407–410.
9. Izuishi K, Sano T, Usuki H, Okano K, Masaki T, Kushida Y, Suzuki Y: Isolated
splenic metastasis of ovarian cancer 20 years after operation: a case
report and literature review. Tumori 2010, 96:784–786.
10. Alloni R, Garberini A, Caputo D, Coppola R: Solitary splenic metastasis of
ovarian carcinoma: report of two cases. Surg Today 2008, 38:1144–1147.
11. Olsen AB, Pargman S, Gillespie T: Solitary splenic metastasis from ovarian
carcinosarcoma: a case report. J Med Case Rep 2011, 5:56.
12. Koh YS, Kim JC, Cho CK: Splenectomy for solitary splenic metastasis of
ovarian cancer. BMC Cancer 2004, 4:96.
13. Aurello P, Petrucciani N, D’Angelo F, Nigri GR, Vitale V, Ravaioli M,
Ramacciato G: Management of solitary splenic metastasis from ovarian
carcinoma: is there an indication for splenectomy? Am Surg 2010,
76:E173–E175.
doi:10.1186/1752-1947-8-154
Cite this article as: Karni et al.: Solitary splenic metastasis of ovarian
carcinoma: a case report. Journal of Medical Case Reports 2014 8:154.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
